AKAMIS BIO
Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.
AKAMIS BIO
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2010-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.akamisbio.com
Total Employee:
51+
Status:
Active
Contact:
+44 (0)1235 835328
Email Addresses:
[email protected]
Total Funding:
132.49 M USD
Technology used in webpage:
SPF Euro DMARC Microsoft Exchange Online Office 365 Mail Google Google Cloud Cloudflare DNS Google Cloud Global Multi-Region Google Cloud Iowa
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
EpicentRx Inc
EpicentRx Inc is a clinical-stage immuno-oncology company.
IMV
IMV is a clinical-stage immuno-oncology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-12-16 | Hybrid BioSystems | Hybrid BioSystems acquired by Akamis Bio | N/A |
Investors List
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Convertible Note - Akamis Bio
Westlake Village BioPartners
Westlake Village BioPartners investment in Convertible Note - Akamis Bio
ARCH Venture Partners
ARCH Venture Partners investment in Convertible Note - Akamis Bio
Salica
Salica investment in Secondary Market - Akamis Bio
IP Group
IP Group investment in Venture Round - Akamis Bio
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Venture Round - Akamis Bio
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - Akamis Bio
Imperial Innovations
Imperial Innovations investment in Series C - Akamis Bio
Woodford Investment Management
Woodford Investment Management investment in Series C - Akamis Bio
Invesco
Invesco investment in Series C - Akamis Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-11 | PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer |
| 2020-03-05 | PsiOxus lures Lillie from Merck to fill CMO position |
Official Site Inspections
http://www.akamisbio.com Semrush global rank: 13.36 M Semrush visits lastest month: 78
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Akamis Bio"
About Us | Akamis Bio | Tumor Gene Therapy
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of … See details»
Akamis Bio - LinkedIn
Akamis Bio | 7,904 followers on LinkedIn. Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer | Akamis is a clinical-stage oncology company whose mission is to ... See details»
Akamis Bio - Crunchbase Company Profile & Funding
Akamis Bio is a clinical-stage oncology company.Headquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 2010 Founders Andrew Coats, … See details»
Akamis Bio 2025 Company Profile: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for Akamis Bio. Use the PitchBook Platform to explore the full profile. See details»
Akamis Bio - 2025 Company Profile & Team - Tracxn
Jun 22, 2025 Akamis Bio is a series D company based in Abingdon (United Kingdom), founded in 2006. It operates as a Developer of gene therapeutics for oncology. Akamis Bio has raised … See details»
Akamis Bio - BIO International Convention 2025
Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in … See details»
Akamis Bio - Overview, News & Similar companies | ZoomInfo.com
Jul 6, 2023 View Akamis Bio (www.akamisbio.com) location in Oxfordshire, United Kingdom , revenue, industry and description. Find related and similar companies as well as employees … See details»
Akamis Bio Strengthens Leadership Team with Key Executive …
Jul 6, 2023 Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherape See details»
Akamis Bio - VentureRadar
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer. To … See details»
Akamis Bio - Craft
Akamis Bio has 5 employees at their 1 location and £218.22 k in annual revenue in FY 2018. See insights on Akamis Bio including office locations, competitors, revenue, financials, executives, … See details»
Home | Akamis Bio | Tumor Gene Therapy
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer. See details»
Akamis Bio: Revenue, Worth, Valuation & Competitors 2025
Akamis Bio has an estimated revenue of -, and 42 employees. Alternatives of Akamis Bio are Dermavant Sciences, Metrum Research Group and Clovis Oncolo... See details»
Akamis Bio Information - RocketReach
Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy … See details»
Akamis Bio Announces $60 Million in Funding Linked to Series A …
Dec 17, 2024 In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn platform-focused collaborations with leaders in the immuno-oncology field including … See details»
Groundbreaking Oncology Company Akamis Bio Secures $60 …
Dec 17, 2024 Akamis Bio, a pioneering clinical-stage oncology company, has successfully secured $60 million in a latest funding round aimed at advancing its innovative T-SIGn® … See details»
Our Board | Akamis Bio | Tumor Gene Therapy
The Akamis Bio board is comprised of proven leaders with diverse backgrounds across the biopharmaceutical industry. See details»
Leadership | Akamis Bio | Tumor Gene Therapy
The Akamis Bio dedicated team of professionals is committed to leveraging our groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. See details»
Join Us Overview | Akamis Bio | Tumor Gene Therapy
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of … See details»
Our Technology | Akamis Bio | Tumor Gene Therapy
Our T-SIGn® therapeutics aim to unlock the full potential of immuno-oncology in the solid tumor setting by enabling a patient’s own immune system to recognize, attack, and clear their cancer. See details»
Our Pipeline | Akamis Bio | Tumor Gene Therapy
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active … See details»